ICU Medical in the news

ICU Medical focuses on disciplined portfolio management, operating gains, and a future shift to shareholder returns after reaching a 2x leverage ratio by the end of 2024.

ICU Medical's stock gained 0.78% to USD 167.58, driven by stable margins and pricing, despite trading at a higher valuation than competitors in the infusion therapy market.

Virginia Sanzone, ICU Medical's VP and General Counsel, sold 4,856 shares for approximately $819,000 amid significant insider selling and the stock being deemed "Significantly Overvalued."

ICU Medical's legal chief sold 4,856 shares of company stock on September 3, 2026, under a preset trading plan.

An ICU Medical officer is planning to sell 4,856 shares of company stock, valued at over $819,000.

ICU Medical's CFO sold $1.1 million in stock while the company reported strong financial performance, an upgraded credit rating, and positive analyst outlooks.

An insider at ICU Medical sold over $1.1 million in shares, as reported in a recent SEC filing.

ICU Medical's CFO, Brian Michael Bonnell, sold 6,381 shares of company stock at $175.00 per share under a pre-arranged trading plan.

ICU Medical's CFO sold shares amidst a trend of insider selling and significant stock overvaluation.

An ICU Medical officer plans to sell over 9,300 shares of common stock worth more than $1.6 million starting in late 2026.

ICU Medical's shares are gaining short-term momentum, trading below estimated intrinsic value due to operational improvements, but face risks from tariffs and regulations as the company prepares for investor conferences.

ICU Medical's stock shows short-term momentum and is considered undervalued by analysts, driven by expected margin improvements and synergy realization, though tariffs and regulatory scrutiny pose risks.

ICU Medical will participate in two investor conferences in September 2026, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference, with webcasts available online.

ICU Medical will participate in two investor conferences in September 2026, including fireside chats and one-on-one meetings, with webcasts available online.

Otsuka ICU Medical is undergoing a $500 million expansion in North Austin to bolster its IV supplies manufacturing and improve supply chain reliability.

Otsuka ICU Medical is expanding its Austin campus by 500,000 square feet to boost IV supply chain reliability and manufacturing capabilities.

Otsuka ICU Medical, a pharmaceutical venture, is investing $500 million to expand its North Austin campus, nearly doubling its size, to boost the U.S. supply of IV solutions.

ICU Medical's Q2 revenue was flat year-on-year, reaching $547.9 million, beating analyst estimates, and the company exceeded EPS guidance and estimates.

ICU Medical's Q2 revenue was flat but beat estimates, with strong EPS performance, while other medical device companies in cardiology, neurology, and vascular care showed mixed results.

Madison Asset Management LLC took a significant position in ICU Medical, as several institutional investors increased their stakes and the company reported strong financial results, despite insider stock sales.